| Liraglutide: can it make a difference in the treatment of type 2 diabetes? | |
| | |
MedLine Citation:
|
PMID: 20949698 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite advances in the management of type 2 diabetes, glycaemic control remains suboptimal for many patients because of the complexities of disease progression and the need to balance improved glycaemic control against adverse treatment effects, particularly weight gain and hypoglycaemia. Thus, the development of new antidiabetes therapies continues in earnest. Incretin hormones have been the recent focus of research, as they account for up to 70% of the insulin response following a meal. There is also a high concordance between the physiological actions of one hormone, glucagon-like peptide-1 (GLP-1), and the therapeutic needs of patients. As native human GLP-1 has a half life of only approximately 2 min, researchers have developed molecules that act as GLP-1 receptor agonists or inhibit the enzyme responsible for GLP-1 degradation (dipeptidyl peptidase-4). Liraglutide, a human GLP-1 analogue sharing 97% of its amino acid sequence identity with native GLP-1, has been approved for use as monotherapy (not in Europe) and in combination with selected oral agents. In this supplement, we summarise key liraglutide data, offer practical insight into what we might expect of liraglutide in clinical use and examine selected case studies. For reasons of the safety and efficacy of GLP-1 receptor agonists, many thought leaders believe that these will become background therapy for majority of patients in the coming years. This supplement will serve as a resource from which readers can extract information concerning the potential benefits for patients who are overweight, losing pancreatic beta-cell function and drifting towards the ravaging effects of chronic hyperglycaemia. |
| | |
Authors:
|
J Unger |
Related Documents
:
|
18957498 - Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet an... 8050588 - Glucagon-like peptide 1: a potent glycogenic hormone. 6397028 - Residual b-cell function in type 1 (insulin-dependent) diabetes mellitus: its relation ... 18640588 - Physiology of incretins (gip and glp-1) and abnormalities in type 2 diabetes. 16452548 - Cortisol correlates with metabolic disturbances in a population study of type 2 diabeti... 8419148 - Alteration of phosphotyrosine phosphatase activity in tissues from diabetic and pregnan... |
Publication Detail:
|
Type: Introductory Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: International journal of clinical practice. Supplement Volume: - ISSN: 1368-504X ISO Abbreviation: Int J Clin Pract Suppl Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-15 Completed Date: 2011-04-27 Revised Date: 2011-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9712380 Medline TA: Int J Clin Pract Suppl Country: England |
Other Details:
|
Languages: eng Pagination: 1-3 Citation Subset: IM |
Affiliation:
|
Catalina Research Institute, Chino, CA 91710, USA. jungermd@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 2*
/
drug therapy,
metabolism Dipeptidyl-Peptidase IV Inhibitors / therapeutic use Disease Progression Drug Approval Drug Therapy, Combination Glucagon-Like Peptide 1 / administration & dosage, adverse effects, analogs & derivatives*, metabolism, pharmacokinetics Half-Life Humans Hypoglycemia / chemically induced Hypoglycemic Agents / pharmacology Insulin / metabolism, therapeutic use Insulin-Secreting Cells / drug effects Obesity / chemically induced Receptors, Glucagon* / agonists, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/Receptors, Glucagon; 0/glucagon-like peptide receptor; 0/liraglutide; 11061-68-0/Insulin; 89750-14-1/Glucagon-Like Peptide 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Looking at ordinary people's tales of living with their mental illness. Interview by Alita Howe.
Next Document: Liraglutide in clinical practice: dosing, safety and efficacy.